shutterstock_1349461187_pavel_kapysh
Pavel Kapysh / Shutterstock.com
16 September 2020AmericasSarah Morgan

Orexo sues Sun Pharma over opioid dependence generic

Swedish pharmaceutical company Orexo has taken India-based Sun Pharmaceutical to court in the US, over its plans to launch a generic version of Orexo’s opioid dependence treatment.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
26 August 2020   Intercept Pharmaceuticals is suing Canadian generics manufacturer Apotex over a proposed version of autoimmune drug Ocaliva.
Americas
23 September 2020   Canada-based Bausch Health has dropped its litigation against Indian generic maker Sun Pharma as part of a settlement agreement.
Big Pharma
24 August 2023   Indian drugmaker had challenged PTAB decision that patent for new version of ruxolitinib was invalid as obvious | Decision hands a victory to US rival.

More on this story

Americas
26 August 2020   Intercept Pharmaceuticals is suing Canadian generics manufacturer Apotex over a proposed version of autoimmune drug Ocaliva.
Americas
23 September 2020   Canada-based Bausch Health has dropped its litigation against Indian generic maker Sun Pharma as part of a settlement agreement.
Big Pharma
24 August 2023   Indian drugmaker had challenged PTAB decision that patent for new version of ruxolitinib was invalid as obvious | Decision hands a victory to US rival.

More on this story

Americas
26 August 2020   Intercept Pharmaceuticals is suing Canadian generics manufacturer Apotex over a proposed version of autoimmune drug Ocaliva.
Americas
23 September 2020   Canada-based Bausch Health has dropped its litigation against Indian generic maker Sun Pharma as part of a settlement agreement.
Big Pharma
24 August 2023   Indian drugmaker had challenged PTAB decision that patent for new version of ruxolitinib was invalid as obvious | Decision hands a victory to US rival.